d Event rate with rivaroxaban was 4/598 (0.67%); event rate with placebo was 0/590 (0%); anticipated absolute effect risk difference with rivaroxaban is 4 more per 1,000 (from 1 less to 17 more). Bibliography: Bauersachs et al21 (EINSTEIN-Extension) TABLE 10 ] Summary of Findings: Apixaban vs Placebo for Extended Treatment of VTEa,b Outcomes No. of Participants (Studies) Follow-up Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with Placebo Risk Difference with Apixaban (95% CI) All-cause mortality 1,669 Moderatec,d because of imprecision (from 14 fewer to 4 more) Recurrent VTE 1,669 High (from 59 fewer to 78 fewer) Major bleeding 1,669 Moderatec,d because of imprecision (from 4 fewer to 8 more) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence. a Patients with VTE who had completed 6 to 12 mo of anticoagulation therapy. b Apixaban 2.5 mg twice-daily dose vs placebo. c Signi cantly wide CIs, including appreciable bene t /harm and no effect line. d Low number of events. 